174
Participants
Start Date
January 31, 2004
Primary Completion Date
May 31, 2013
Study Completion Date
May 31, 2013
Gefitinib
ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
Anastrozole
1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
Research Site, La Jolla
Research Site, San Diego
Research Site, Orlando
Research Site, Lafayette
Research Site, Rockville
Research Site, Columbia
Research Site, Omaha
Research Site, Las Vegas
Research Site, Voorhees Township
Research Site, Albuquerque
Research Site, Lake Success
Research Site, Cincinnati
Research Site, Allentown
Research Site, Sioux Falls
Research Site, Houston
Research Site, Temple
Research Site, Santiago de Cali
Research Site, Aguascalientes
Research Site, Guadalajara
Research Site, Morelia
Research Site, Barcelona
Research Site, Barquisimeto
Research Site, Caracas
Research Site, Maracaibo
Research Site, Puerto Ordaz and San Felix
Research Site, San Cristóbal
Research Site, Valencia
Lead Sponsor
AstraZeneca
INDUSTRY